证券代码：600299 证券简称：安迪苏 公告编号：2025-014 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024 年年度股东大会 (二)股东大会召集人：董事会 蓝星安迪苏股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 3 月 24 日 14 点 00 分 召开地点：北京市朝阳区北土城西路 9 号蓝星大厦会议室 (五)网络投票的系统、起止日期和投票时间。 股东大会召开日期：2025年3月24日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 3 月 24 日 至 2025 年 3 月 24 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段， ...

第九届监事会第四次会议 决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（简称"安迪苏"或"公司"）第九届监事会第四次会 议于 2025 年 2 月 27 日以通讯表决的方式召开。监事会会议通知和材料于 2025 年 2 月 17 日以电子邮件方式发出。会议应参加表决监事 3 人，实际参加表决监事 3 人。本次会议符合《中华人民共和国公司法》和《蓝星安迪苏股份有限公司章程》 （以下简称"《公司章程》"）的有关规定。本次会议由监事会主席王岩先生召集 和主持。 参加会议的监事表决通过以下议案： 1. 审议通过关于《2024 年年度报告及摘要》的议案 《2024 年年度报告及摘要》内容详见上海证券交易所网站：www.sse.com.cn； 《2024 年年度报告摘要》详见《中国证券报》和《证券日报》。 公司监事会根据《上海证券交易所股票上市规则》和《公开发行证券的公司 信息披露内容与格式准则第 2 号——年度报告的内容与格式》的有关要求，对董 事会编制的公司《2024 年年度报告及摘要》进行了认真严格 ...

Financial Performance - The net profit attributable to shareholders for the year 2024 is RMB 1,204,325,915[7]. - The total distributable profit for the parent company as of December 31, 2024, is RMB 998,212,697[7]. - The proposed cash dividend is RMB 1.2 per 10 shares, totaling RMB 321,828,152.76, which is subject to approval at the annual general meeting[7]. - The total expected cash dividend for 2024 is RMB 482,742,229.14, accounting for 40.08% of the net profit attributable to shareholders[8]. - The company's operating revenue for 2024 reached CNY 15.53 billion, a 17.83% increase from CNY 13.18 billion in 2023[26]. - Net profit attributable to shareholders surged to CNY 1.20 billion, marking a significant increase of 2,208.66% compared to CNY 52.17 million in the previous year[26]. - The diluted earnings per share for 2024 were CNY 0.45, a remarkable increase of 2,150.00% from CNY 0.02 in 2023[27]. - The company's net cash flow from operating activities was RMB 2,944,669,481, a 6.53% increase from the previous year[77]. - Operating costs increased to RMB 10,840,773,006, reflecting a rise of 4.59% year-on-year[77]. - The gross profit margin for the nutrition and health industry was 30.21%, an increase of 9 percentage points compared to the previous year[79]. Dividends and Shareholder Returns - The company plans to distribute an interim cash dividend of RMB 0.6 per 10 shares, totaling an estimated RMB 160,914,076.38, approved at the first extraordinary general meeting in February 2025[7]. - The company paid dividends of RMB 160,914,076 in 2024[93]. - The company has a long-term dividend policy adjustment in place, aiming to enhance shareholder returns over the next three years (2024-2026)[180]. Acquisitions and Market Position - The company completed the acquisition of Nor-Feed, a French group specializing in plant-based specialty ingredients for animal feed, in February 2023[16]. - The acquisition of FRAmelco and Nor-Feed has strengthened the company's leadership in the rapidly growing "nutrition promotes health" market[41]. - The company has a strong market position as a leading supplier of liquid methionine and aims to become the largest methionine producer globally[41]. Research and Development - The company plans to continue investing in R&D and operational efficiency to support future business growth despite increased costs in these areas[28]. - Research and development expenses totaled RMB 562,662,650, accounting for 3.62% of operating revenue[89]. - The newly established R&D innovation center in China has been operational since early 2022, providing strong technical support for the company's business[52]. - The company received over 70 applications for its new R&D fund (ARG) in 2024, aimed at addressing major challenges in the feed industry, including sustainability and antibiotic bans[71]. Sustainability and Environmental Impact - The company achieved a 40% reduction in greenhouse gas emissions compared to 2015 levels, surpassing its 2025 target[43]. - The company is committed to sustainable development, aligning its goals with international standards such as the Paris Agreement and the UN Sustainable Development Goals[44]. - The company is focusing on reducing production costs and carbon footprint through ongoing improvements in methionine production processes[52]. - The company is committed to sustainable production methods, which is increasing the demand for optimal feed solutions including amino acids and probiotics[137]. Operational Efficiency and Cost Management - The company achieved a reduction in regular operating costs totaling CNY 179 million for the year 2024, contributing to improved profitability[28]. - The company is focusing on enhancing feed efficiency and reducing costs through enzyme products and emulsifiers, supporting overall production performance and sustainability[60]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[186]. Market Expansion and Growth Strategy - The company aims to enhance its product management by categorizing its offerings into functional and specialty products starting in 2024[80]. - The company is actively seeking external acquisition opportunities to accelerate growth and expand its product portfolio in the specialty products and animal nutrition health sectors[141]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[188]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[11]. - The company faces risks from supply-demand imbalances in the methionine market, influenced by global capacity changes and external factors[151]. - Andy Su's operations are subject to industrial risks, including potential civil and environmental liabilities related to its production processes[159]. Corporate Governance - The company adheres to corporate governance standards, ensuring compliance with legal requirements and protecting shareholder interests[177]. - The company has established four specialized committees under the board, including an audit committee and a strategic and sustainable development committee[178]. - The company has emphasized the importance of independent directors' participation in board meetings, ensuring governance and oversight[200].

证券代码：600299 证券简称：安迪苏 公告编号：2025-009 蓝星安迪苏股份有限公司 第九届董事会第四次会议 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（简称"安迪苏"或"公司"）第九届董事会第四 次会议于2025年2月27日以通讯表决的方式召开。董事会会议通知和材料于2025 年 2 月 17 日以电子邮件方式发出。会议应参加表决董事 9 人，实际参加表决董事 9 人。本次会议符合《中华人民共和国公司法》和《蓝星安迪苏股份有限公司章 程》的有关规定。本次会议由董事长郝志刚先生召集和主持。公司监事和部分高 管列席会议。 参加会议的董事表决通过以下议案： 1. 审议通过关于《2024 年年度报告及摘要》的议案 《2024 年年度报告及摘要》详见上海证券交易所网站：www.sse.com.cn； 《2024 年年度报告摘要》详见《中国证券报》和《证券日报》。 审计、风险及合规委员会审议同意上述议案。 会议以 9 票同意，0 票反对，0 票弃权的表决结果审议通过了议案。 2. 审议通过关 ...

关于蓝星安迪苏股份有限公司 2025 年第一次临时股东大会 之法律意见书 致：蓝星安迪苏股份有限公司 北京市金杜律师事务所上海分所 北京市金杜律师事务所上海分所（以下简称金杜）接受蓝星安迪苏股份有限公司 （以下简称安迪苏或公司）的委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会（以下简称中国证监会）《上市公司股东大会规则》（以下简称《股东大会规 则》）等中华人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括 香港特别行政区、澳门特别行政区和台湾地区）现行有效的法律、行政法规及规范性 文件和现行有效的《蓝星安迪苏股份有限公司章程》（以下简称《公司章程》）有关 规定，指派律师出席了公司于 2025 年 2 月 7 日召开的 2025 年第一次临时股东大会（以 下简称本次股东大会），并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，金杜律师审查了安迪苏提供的以下文件，包括但不限于： 1. 经蓝星安迪苏股份有限公司 2023 年年度股东大会审议通过的《蓝星安迪苏股 份有限公司章程》（以下简称《公司章程》）； ...

证券代码：600299 证券简称：安迪苏 公告编号：2025-008 蓝星安迪苏股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 2 月 7 日 (二)股东大会召开的地点：北京市朝阳区北土城西路 9 号蓝星大厦会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 248 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 2,331,113,975 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 86.9202 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长郝志刚先生主持大会，采取现 场投票和网络投票相结合的表决方式。会议召集、召开程序符合《中华人民共 ...

一、 恺迪苏产生亏损的主要原因 安迪苏注册在香港的全资子公司蓝星安迪苏营养集团有限公司和恺勒司注册 在香港的全资子公司在香港共同成立了一家合资公司恺迪苏，双方共投资 8,000 万美元，各占 50%的股权。恺迪苏有限公司于 2020 年 9 月在重庆投资建设全资子 公司恺迪苏（重庆）有限公司，该公司成为世界上首个规模化生产单细胞蛋白产 品的示范性工厂。由于该生物技术复杂性，创新斐康®蛋白技术较预期需要更长 的时间才能实现全面工业化和商业化，恺迪苏 2024 年度净利润约为-17,799.13 万 元（未经审计），预计减少公司 2024 年合并报表净利润 8,899.57 万元（未考虑所 得税影响，未经审计）。 二、风险提示 以上数据仅为初步核算数据，准确财务数据以公司正式披露的经审计后的 2024 年年报为准，敬请广大投资者注意投资风险。 证券代码：600299 证券简称：安迪苏 公告编号：2025-007 蓝星安迪苏股份有限公司 关于合资企业发生亏损的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份 ...

蓝星安迪苏股份有限公司 2025 年第一次临时股东大会会议资料 蓝星安迪苏股份有限公司 2025 年第一次临时股东大会 会议资料 二零二五年二月七日 1 蓝星安迪苏股份有限公司 2025 年第一次临时股东大会会议资料 蓝星安迪苏股份有限公司 2025 年第一次临时股东大会 重要提示： 现场会议时间：2025 年 2 月 7 日（星期五）下午 14:30 会议地点：北京市朝阳区北土城西路 9 号蓝星大厦会议室 主持人：董事长郝志刚 参加会议人员： | 议程 | | --- | 蓝星安迪苏股份有限公司 2025 年第一次临时股东大会 会议须知 蓝星安迪苏股份有限公司 董事会办公室 | 时间 | 内容 | | --- | --- | | 14:30-14:35 | 会议议程介绍 | | 1 | 主持人宣布会议开始并致欢迎辞 | | 2 | 董事会秘书宣读投票规则和注意事项 | | 3 | 推举计票人和监票人 | | 14:35-14:50 | 与会者审议以下议案 | | 1 | 中期分红方案 | | 2 | 向公司合资企业提供财务资助 | | 14:50-15:30 | 股东提问&回答及现场表决 | | 1 | 股 ...

Corporate Changes - Vanke A's chairman Yu Liang resigned due to work adjustments but will continue as a board member and executive vice president [1] - Zhu Jiuxing resigned from all positions due to health reasons, while Zhu Xu also resigned from several roles but will remain with the company [1] - Senba Sensor's actual controller and chairman, Shan Senlin, has been placed under detention, but other executives are continuing their duties [2] Mergers and Acquisitions - Shida Group plans to acquire 51% of Shuchan Ming Shang's equity for cash, which will make it the controlling shareholder [4] - Bid Pharma intends to acquire control of Weibo Investment through a share issuance, aiming to strengthen its product line in drug molecular blocks and scientific reagents [4] - Lingrui Pharmaceutical plans to acquire 90% of Yingu Pharmaceutical for 704 million yuan, enhancing its product line [4] - Huamao Technology intends to acquire 10% of Shenzhen Fuchuang for 85 million yuan, making it an associate company [5] - TCL Zhonghuan plans to acquire 100% of SPML for 58.6 million USD to enhance its global business [6] Financial Performance - Andisou expects a net profit increase of 2208.04% in 2024, driven by strong sales of methionine and a rebound in vitamin prices [7] - Xinchai expects a net profit increase of 106.52% to 169.1% in 2024, benefiting from improved gross margins and tax incentives [8] - Shangluo Electronics anticipates a net profit increase of 85.34% to 126.52% in 2024, supported by a recovery in traditional electronics and growth in AI and new energy sectors [9] - Nanjing Bank reported a net profit of 20.177 billion yuan in 2024, a 9.05% increase year-on-year [12] - Vanke A expects a net loss of approximately 45 billion yuan in 2024, significantly down from a profit of 12.163 billion yuan in the previous year [26] Contracts and Projects - Shuangjie Electric won a bid for a project worth approximately 366 million yuan from Southern Power Grid [27] - Hengshang Energy reported a 5.36% increase in new project amounts in 2024, totaling 2.084 billion yuan [28] - China Aluminum International signed new contracts totaling 30.826 billion yuan in 2024, with a significant increase in industrial projects [29] Strategic Initiatives - Vanke A plans to transfer investment rights in the Hongshu Bay project for 1.292 billion yuan to its largest shareholder, enhancing liquidity [30] - Wolong Electric plans to sell stakes in several subsidiaries to focus on its core motor and drive control business [30] - Shanghai Pharmaceuticals intends to invest 1 billion yuan in a biopharmaceutical merger fund to support the industry [31] - Dongfulong plans to invest 200 million yuan in a biopharmaceutical merger fund, focusing on key areas of the Shanghai biopharmaceutical industry [32]

Financial Performance - The company expects a net profit attributable to shareholders of RMB 1.204 billion for 2024, an increase of RMB 1.152 billion, representing a year-on-year growth of 2208.04%[3] - The net profit excluding non-recurring gains and losses is projected to be RMB 1.346 billion, up by RMB 1.333 billion, reflecting a year-on-year increase of 10256.90%[3] - Revenue is anticipated to grow by 18% to RMB 15.53 billion, with gross profit increasing by 67% to RMB 4.69 billion, resulting in a gross margin improvement of 9 percentage points to 30%[5] - The EBITDA margin excluding non-recurring gains and losses is expected to rise to 22%, an increase of 8 percentage points from 14% in 2023[7] Sales and Market Growth - The company achieved a strong sales growth of 24% in methionine, with both liquid and solid methionine products reaching historical sales highs[6] - The company continues to expand its market presence in China and Southeast Asia, particularly through the joint venture with Calysta, focusing on innovative protein solutions[6] Cost Management - The company has successfully reduced regular operating costs by RMB 179 million in 2024, contributing to improved cost efficiency[6] - The company has achieved a significant reduction in costs exceeding RMB 1 billion over the past six years, enhancing its competitive cost structure[7] Cash Flow and Financial Position - Cash balance as of December 31, 2024, is projected to be RMB 1.266 billion, an increase of RMB 260 million compared to December 31, 2023[7] Performance Forecast - The company emphasizes that the performance forecast is preliminary and subject to final audited results in the annual report[8]